Delivery Order SPE2DB20D3103-SPE2DB25FQ4Z6
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,078.27 to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of September 15, 2025. The award supports pharmaceutical procurement for federal medical supply chains, with performance occurring at AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 12, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $41,765.78 under a firm fixed-price contract. This is a non-set-aside, competitively awarded delivery order to be fulfilled at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of June 13, 2025. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $25,982.33 on August 21, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $35,600.20 on August 29, 2025, for Dupixent 300 mg/2 mL pen auto-injectors. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by September 2, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $26,328.21 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a $31,503.39 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This competitively awarded, firm fixed price contract is scheduled for completion by August 15, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order represents a...
- The Defense Logistics Agency awarded a $68,986.58 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a firm fixed price transaction under an existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency awarded a $56,394.80 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's distribution...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $11,758.26. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 8, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions,...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ4Z6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $34,236.08 on September 27, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 29, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a primary pharmaceutical distributor for federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. This comprehensive global pharmaceutical support vehicle enables AmerisourceBergen to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. Dupixent (dupilumab) is a specialty biologic medication commonly used to treat moderate-to-severe eczema, asthma, and allergic conditions, underscoring the DLA's commitment to providing advanced pharmaceutical therapies to military personnel and beneficiaries through its established prime vendor relationships.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.2k | 9/27/25 |